H19 and urinary bladder neoplasm: The therapeutic potency of the vector was tested by 3 intratumoral injections, at two-day intervals, of 25 μg of H19-DTA-P4-DTA or of the control vector (H19-Luc-P4-Luc), into each heterotopic bladder tumor.